SIOX VS BLPH Stock Comparison

Performance

SIOX
10/100

SIOX returned -58.25% in the last 12 months. Based on the other stocks in it's sector, it's performance is below average giving it a grade of 10 of 100.

BLPH
10/100

BLPH returned -90.60% in the last 12 months. Based on SPY's performance of -11.83%, its performance is below average giving it a score of 10 of 100.

Forecast

SIOX
82/100

The 38 analysts offering 12-month price forecasts for SIOX have an average target of 0, with a high estimate of 0 and a low estimate of 0 giving it a grade of 82 of 100.

BLPH

"Forecast" not found for BLPH

Technicals

SIOX
86/100

Based on a multitude of SIOX's technicals indicators, it receives a grade of 85 of 100.

BLPH
11/100

BLPH receives a 10 of 100 based on 14 indicators. 1 are bullish, 12 are bearish.

Volatility

SIOX
10/100

SIOX had a -3,007.89% lower max drawdown compared to SPY over the last 12 months giving it a grade of 10 of 100.

BLPH
57/100

BLPH has had a higher than average amount of volatility over the last 12 months giving it a score of 57 of 100.

Dividend

SIOX
10/100

SIOX does not have a dividend payout ratio.

BLPH

"Dividend" not found for BLPH

Profit

SIOX
10/100

Could not get data for SIOX.

BLPH
10/100

Out of the last 20 quarters, BLPH has had 2 profitable quarters and has increased their profits year over year on 1 of them.

Analyst Price Targets

SIOX

"Analyst Price Targets" not found for SIOX

BLPH
75/100

1 analysts offer 12-month price targets for BLPH. Together, they have an average target of 19, the most optimistic target put BLPH at 19 within 12-months and the most pessimistic has BLPH at 19. These analyst ratings are from our partners at Financial Modeling Prep and Alpha Vantage.

Earnings

SIOX

"Earnings" not found for SIOX

BLPH
36/100

BLPH has missed earnings 3 times in the last 20 quarters.

All score calculations are broken down here to help you make more informed investing decisions

Sio Gene Therapies Inc. Common Stock Summary

Nasdaq / SIOX

Healthcare

Biotechnology

Sio Gene Therapies Inc., a clinical-stage company, focuses on developing gene therapies to radically transform the lives of patients with neurodegenerative diseases. It has a license agreement with Oxford BioMedica (UK) Ltd. to develop and commercialize AXO-Lenti-PD and related gene therapy products; and The University of Massachusetts Medical School to develop and commercialize gene therapy product candidates, including AXO-AAV-GM1 and AXO-AAV-GM. The company was formerly known as Axovant Gene Therapies Ltd. and changed its name to Sio Gene Therapies, Inc. in November 2020. Sio Gene Therapies, Inc. was incorporated in 2014 and is based in New York, New York.

Bellerophon Therapeutics, Inc. Summary

Nasdaq / BLPH

Healthcare

Biotechnology

Bellerophon Therapeutics, Inc., a clinical-stage therapeutics company, focuses on the development of products for the treatment of cardiopulmonary diseases in the United States. Its product includes INOpulse, a proprietary pulsatile nitric oxide delivery platform for the treatment of pulmonary hypertension. The company engages in the development of INOpulse that is in Phase 3 clinical trial for the treatment of pulmonary hypertension associated with fibrotic interstitial lung disease; which has completed Phase 2a clinical trial for pulmonary hypertension associated with chronic obstructive pulmonary disease; and that has completed Phase 2 dose escalation stage for pulmonary hypertension associated with sarcoidosis, as well as for chronic thromboembolic pulmonary hypertension and pulmonary hypertension associated with pulmonary edema from high altitude sickness. The company was formerly known as Ikaria Development LLC and changed its name to Bellerophon Therapeutics, Inc. in January 2014. Bellerophon Therapeutics, Inc. was founded in 2009 and is headquartered in Warren, New Jersey.

Power up your portfolio